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Introduction
The platelet surface membrane contains an estimated 26,000-The glycocalicin fragment contains the GPIb receptor site for von Willebrand factor (7) and thrombin (4, 5) .
In addition to the platelet surface and plasma pools of GPIb, there may be a third. intraplatelet pool of GPIb. Both Asch et al. (8) and Weficel-Drake et al. (9) , using frozen thinsection imtnunoelectron microscopy, have recently described an intraplatelet pool of GPIb, located on the intraluminal face of vacuolar structures (9) . However, this putative intraplatelet pool of GPIb has not been quantitated or functionally characterized.
Ifti the present study, we demonstrate that platelet storage results in a redistribution of the platelet surface and plasma pools of GPIb. This redistribution suggested the presence of a large intraplatelet pool of GPIb, which we have now quantitated.
Methods
Monoclonal antibodies. We utilized three murine monoclonal antibodies (6D1, WM23, and 3G6) directed against the glycocalicin portion of the a-chain of platelet membrane GPIb. 6D1 and WM23 were generously provided by Drs. Barry S. Coller (SUNY, Stony Brook, NY) and Michael C. Berndt (University of Sydney, Australia), respectively. 3G6 was prepared in our laboratory by standard hybridoma technology (10) after injection of mice with glycocalicin, purified as previously described (I 1). 6DI is directed at the von Willebrand factor binding site on the glycocalicin portion of the a-chain of GPIb (3) . WM23 and 3G6 are also directed against the glycocalicin portion of the a-chain ofGPIb, but not against the von Willebrand factor binding site (Berndt et al. [12] and B. Adelman, unpublished observations). WM23 has been characterized as being directed against the macroglycopeptide portion of glycocalicin, rather than the terminal protein portion that contains the von Willebrand factor and 6D1 binding sites (M. C. Berndt, personal communication). Unlike 6D1, both 3G6 and WM23 recognize their respective antigens in Western blots. After complete platelet solubilization with sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) and Western blotting, both 3G6 and WM23 (M. C. Berndt, personal communication) recognize only a single band (GPIb) in both reduced and nonreduced gels. As a control antibody in the flow cytometry assay, we utilized OX6 (provided by Dr. Bruce Woda, University of Massachusetts Medical School), a mouse monoclonal antibody of the same IgG subtype as 6D1 and WM23, but directed at rat lymphocyte Ia antigen.
Platelet concentrate preparation and storage. Blood from five different normal donors was collected into citrate-phosphate-dextrose solution and individual platelet concentrates, resuspended in -50 ml oftheir own plasma, were prepared in PL-732 bags (Fenwal Laboratories, Morton Grove, IL) by standard methods (13). After being left stationary at 220C for 1 h, the platelet concentrates were stored in a linear platelet reciprocator model LPR-l (Melco Engineering Corp., Glendale, CA) with gentle horizontal agitation at 70 rpm for 5 d at 220C. Immediately after preparation (day 0) and then daily for 5 d, samples from the platelet concentrates were aseptically withdrawn through a sample port into a syringe containing EDTA and aprotinin (Sigma Chemical Co., St Louis, MO) (final concentrations: EDTA 10 mM, aprotinin 1,000 KIU/ml). For all samples from all donors, each assay (flow cytometric analysis ofplatelet surface GPIb, enzyme-linked immunosorbent assay (ELISA) for plasma glycocalicin, and platelet count) was performed at the same time using the same reagents. There was no platelet clumping in the concentrates, as determined both by direct inspection and phase microscopy performed daily for the 5 d of storage. All donors were normal adult volunteers who had given written informed consent for blood collection.
Platelet counts. Platelet counting was performed in a Sysmex automated hematology analyzer model CC-800 (Toa Medical Electronics, Carson, CA).
Flow cytometric analysis ofplatelet surface GPIb. Daily samples removed from the platelet concentrates were fixed in 1% formaldehyde for 30 min at 220C. As previously described (14-16), platelets were washed, incubated with either a saturating concentration of monoclonal antibody 6D1 or the irrelevant monoclonal antibody OX6, washed again, incubated with a saturating concentration of fluorescein isothiocyanate-labeled goat anti-mouse IgG antibody (Cooper Biomedical, Malvern, PA), washed again, and analyzed in a FACS 440 (Becton Dickinson FACS Systems, Mountain View, CA). For each sample the fluorescence signal from 10,000 individual cells was measured. Three-dimensional contour maps were ungated. All histograms were gated by forward light scatter to include 90% of cells (excluding 5% of both the smallest and largest cells), with the approximate median being determined by 2-,gm diam plastic beads (Polysciences, Inc., Warrington, PA). Based on their characteristic forward and orthogonal light scatter profiles (and as confirmed by appropriate monoclonal antibodies), no red cells, lymphocytes, monocytes, or granulocytes were among the cells assessed in any of the gated histograms or ungated contour maps. Results were expressed in one ofthree ways: (a) the number of platelets with a completely negative surface GPIb phenotype, as determined by the percentage of platelets that, after incubation with monoclonal antibody 6D1 followed by goat anti-mouse antibody, did not have fluorescence > 95% of platelets incubated with monoclonal antibody OX6 followed by goat antimouse antibody; (b) relative specific fluorescence (RSF) (arbitrary linear units), calculated from the mean channel number ofall platelets, as previously described (15) ; (c) RSF of surface GPIb-positive platelets, calculated as previously described (15) but using the mean channel number of only those platelets that, after incubation with 6D1 followed by goat antimouse antibody, had fluorescence > 95% of platelets incubated with OX6 followed by goat anti-mouse antibody.
ELISA for plasma glycocalicin. Daily samples removed from the platelet concentrates were centrifuged at 2,000 g for 10 min at 22°C and the upper two-thirds ofthe plasma was removed. In control assays, the plasma was centrifuged at 22°C for an additional 2 h at 100,000 g. All plasma samples were stored at -70°C until assayed. After thawing, the samples were centrifuged again at 8,000 g for 4 min at 22°C. The final plasma supernatants were assessed for glycocalicin content by ELISA, as previously described (7, 1 1 (11) , resuspended at a concentration of 1.0 X 106/1I in Tris-EDTA-buffered saline (10 mM Tris, 0.15 M NaCI, 20 mM EDTA, pH 7.4), and incubated for 1 h at 22°C with or without 1 casseinolytic unit/ml of plasmin (KABI through Helena Laboratories). The reaction was stopped by adding aprotinin in excess of the amount needed to totally inhibit plasmin activity (1 1). The platelet suspensions were then centrifuged (2,000 g, 10 min, 22°C) and the glycocalicin content of the supernatants determined by ELISA, as described above. The platelet pellets were resuspended in Tris-EDTA-buffered saline and fixed overnight at 4°C in 1% formaldehyde. The fixed platelets were washed three times in Tris-buffered saline (2,000 g, 10 min, 22°C) and resuspended in a concentration of 25,000/4d. Plasmintreated and non-plasmin-treated platelets were then analyzed by flow cytometry for content of surface GPIb, as described above.
Bernard-Soulier syndromepatient. M.R. is a 26-yr-old woman with the Bernard-Soulier syndrome, as previously described (15) . Three lines of evidence suggested that the ELISA was correctly quantitating plasma glycocalicin. First, the glycocalicin concentration of normal donor plasma and purified glycocalicin was the same whether the samples were quantitated separately or in a mixture. Secondly, as stated above, we obtained plasma glycocalicin levels on day 0 which were comparable to those obtained in normal donors by Coller et al. (6) . Thirdly, in separate experiments, treatment of washed platelets (1.0 X 106/s1) with plasmin 1 casseinolytic unit/ml for 1 h at 220C resulted in complete cleavage of platelet surface GPIb, as quantitated by antibody 6D11 and flow cytometry (as previously described [ 14] ), and release of 36,360±1,390 (mean±SEM, n = 4) molecules of glycocalicin per platelet, as quantitated by antibody 6D1 in the ELISA (Table I ). This number is consistent with the number ofplatelet surface GPIb molecules determined by other investigators (1, 2) .
Assuming then that there were initially 36,360 molecules of GPIb on the surface of each platelet, the observed increase in plasma glycocalicin concentration between days 0 and 5 corresponded to 1.3 times the total amount of glycocalicin present on the surface of all the platelets. Fig. 2 (Fig. 2: solid circles, solid line).
The flow cytometric method enabled us to determine that the storage-related increase in the total number of platelet surface GPIb molecules per platelet (Fig. 2) was not the result ofa uniform increase in the number of GPIb molecules on all platelets. As shown in Fig. 3 , storage ofplatelets resulted in the appearance of two phenotypically distinct subpopulations of platelets: one surface GPIb-positive, the other surface GPIbnegative. With increasing length of storage, platelets with the surface GPIb-negative phenotype comprised an increasing proportion of the total platelet number, comprising 12% of all platelets by day 5 (Fig. 4 A) . After 24 h, platelets with the surface GPIb-positive phenotype had a 28% increase in the number of surface GPIb molecules, as determined by flow cytometry (Fig. 4 B) . Over the ensuing 4 d of storage, platelets with the surface GPIb-positive phenotype gradually expressed less surface GPIb molecules, but by day 5 of storage there was still a 16% increase in the number of surface GPIb molecules compared with this subpopulation of platelets on day 0 (Fig. 4   B subpopulation of platelets, suggesting that the surface GPIbnegative platelets were smaller than the surface GPIb-positive platelets.
The unexpectedly large increase in plasma glycocalicin concentration during storage of platelet concentrates, in the face of the lack of an overall decrease in platelet surface GPIb, suggested the existence ofan additional large intraplatelet pool of GPIb. In order to quantitate this putative intraplatelet pool of GPIb, the total platelet GPIb content was determined by SDS-PAGE. Solubilized whole platelets were compared to a standard curve of known amounts of purified glycocalicin (Fig. 5) . The total number of GPIb molecules per platelet detected by SDS-PAGE was 151,800±3,500 (mean±SEM, n = 6) ( Table I ). The total number ofGPIb molecules per platelet was therefore approximately fourfold greater than the number of GPIb molecules present on the platelet surface (Table I) , suggesting the presence ofan intraplatelet pool ofGPIb which was approximately threefold larger than the platelet surface pool of GPIb.
In order to further substantiate our finding that the total platelet GPIb content was so much greater than the platelet surface pool, we quantitated the total platelet GPIb content by a different method: ELISA of 1% Triton X-100-solubilized platelets. The total number of GPIb molecules per platelet detected by ELISA using 6D1 (the monoclonal antibody directed against the von Willebrand factor binding site on GPIb) was 182,330±6,970 (n = 9). The total number of GPIb molecules per platelet detected by ELISA using WM23 (the monoclonal antibody directed against the macroglycopeptide portion of the a-chain of GPIb) was 145,090±6,050 (n = 9) (Table I ).
In the assay for total platelet GPIb content determined by ELISA of Triton X-100 solubilized platelets, the following three control experiments were performed: (a) replacement of platelets with buffer only, then treating with 1% Triton X-100, resulted in the detection of no GPIb (n = 3), thereby demonstrating that, at the dilutions used, Triton X-100 did not interfere with the ELISA; (b) treatment of normal donor plasma with 1% Triton X-100 resulted in a plasma glycocalicin level, Forward Light Scatter a as determined by 6D1, which was 94.4±10.5% (mean±SEM, n = 3) of the plasma glycocalicin level of untreated normal plasma, thereby demonstrating that 1% Triton X-100 treatment of glycocalicin did not reveal additional epitopes recognizable by 6D1; (c) within the range 1-10 nM, addition of various concentrations of purified glycocalicin to the Triton X-100 platelet lysates had the predicted additive effect on the GPIb concentration. All platelet lysate samples were therefore assayed at a dilution within this range. Fox (18, 25) found that 60-70% of platelet GPIb is bound to actin filaments and that, after 1% Triton X-100 platelet solubilization, high-speed centrifugation is required for their sedimentation. We therefore studied the effect of centrifugation conditions on quantitation of GPIb in whole-platelet lysates. With all other assay conditions kept constant, changing the centrifugation conditions of 1% Triton X-100 platelet lysates from our standard (8,000 g for 4 min) to those ofFox (18) (100,000 g for 3 h) resulted in a 52.8±4.4% (mean±SEM, n Fox (18, 25) reported that 60-70% of platelet GPIb is bound to actin filaments present in the platelet skeleton. Fox (18) demonstrated that, after 1% Triton X-100 solubilization of platelets in the presence of 1 mg/ml leupeptin, the actin filament-associated GPIb is recovered mainly with those filaments which require high-speed centrifugation (100,000 g for 3 h) for their sedimentation, whereas low-speed centrifugation (15,600 g for 4 min) results in most of the GPIb being in the supernatant. Likewise, Solum and Olsen (29) demonstrated that solubilization of platelets with 1% Triton X-100 in the presence of leupeptin resulted in essentially all the GPIb being in the supernatant after low-speed centrifugation (8,000 g for 4 min) of the lysate. Consistent with the data of both Fox and Solum and their co-workers, we found that, after 1% Triton X-100 solubilization of platelets in the presence of 1 mg/ml leupeptin, alteration of the centrifugation conditions of the platelet lysates from our standard (8,000 g for 4 min) to those of Fox (18) (100,000 g for 3 h) resulted in a 52.8±4.4% (mean±SEM, n = 4) decrease in the GPIb content of the supernatant, as determined by ELISA. We conclude that our low-speed centrifugation conditions do not sediment the majority ofactin filament-associated GPIb and that ELISA ofthis supernatant assays most of the total platelet GPIb content.
The present studies did not enable us to determine that the surface GPIb-negative phenotype was the result of a complete deficiency of platelet surface GPIb. A partial deficiency of the platelet surface GPIb molecule or a more subtle biochemical modification ofthe antibody binding site are alternative explanations for the lack ofbinding of monoclonal antibody 6Dl to the subpopulation of platelets with the surface GPIIb-negative phenotype. Although thrombin can result in decreased binding of 6D1 to platelets (16), generation of thrombin would not account for the marked increase in plasma glycocalicin (16).
The present data are relevant to the clinical infusion of platelet concentrates into patients, because (a) monoclonal antibody 6D1 is directed against the GPIb receptor for von Willebrand factor (3), (b) this receptor has a central role in platelet adhesion to damaged blood vessel walls (1), and (c) our experiments were performed on platelet concentrates prepared exactly as for clinical transfusion purposes (13). Studies by other investigators of the GPIb content of stored platelet concentrates have yielded apparently confficting results. In two separate radioligand-binding assays utilizing a monoclonal antibody (AN5 1) directed at GPIb and Maclura pomifera lectin, respectively, Taylor and Anstee (30) found no decrease in the surface GPIb content ofstored platelet concentrates after 3 d of storage at 22°C. Using SDS-PAGE of whole platelets and periodic acid Schiffs reagent staining, George (31) and Bolin et al. (32) found a 49% and a 29% decrease, respectively, in the total GPIb content of stored platelet concentrates after 3 d of storage at 22°C. The data ofall these investigators (30) (31) (32) are, however, consistent with the present finding ofa redistribution of GPIb molecules.
